The DOI matches its Crossref record; 80 of the 80 references it cites were found in a registry or an index.
Urinary Bladder Cancer in Dogs, a Naturally Occurring Model for Cancer Biology and Drug Development
Open accessAbstract
Each year more than 65,000 people are diagnosed with urinary bladder cancer, and more than 14,000 people die from the disease in the United States. Studies in relevant animal models are essential to improve the management of bladder cancer. Naturally occurring bladder cancer in dogs very closely mimics human invasive bladder cancer, specifically high-grade invasive transitional cell carcinoma (TCC; also referred to as invasive urothelial carcinoma) in cellular and molecular features; biological behavior, including sites and frequency of metastasis; and response to therapy. Canine bladder cancer complements experimentally induced rodent tumors in regard to animal models of bladder cancer. Results of cellular and molecular studies and -omics analyses in dogs are expected to lead to improved detection of TCC and preneoplastic lesions, earlier intervention, better prediction of patient outcome, and more effective TCC management overall. Studies in dogs are being used to help define heritable risks (through very strong breed-associated risk) and environment risks and to evaluate prevention and treatment approaches that benefit humans as well as dogs. Clinical treatment trials in pet dogs with TCC are considered a win-win scenario by clinician scientists and pet owners. The individual dog benefits from effective treatment, the results are expected to help other dogs, and the findings are expected to ultimately help humans with TCC. This article provides an overview of canine TCC, a summary of the similarities and differences between canine and human invasive TCC, and examples of the types of valuable translational research that can be done using dogs with naturally occurring TCC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Roberts, J. T., von der Maase, H., Sengeløv, L., Conte, P., Dogliotti, L., Oliver, R. T. D., Moore, M. J., Zimmermann, A., & Arning, M. (2006) · Annals of Oncology · doi:10.1093/annonc/mdj965 · Cited by 125
RetractedComprehensive molecular characterization of urothelial bladder carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/za09-dk57 · Cited by 2,990
A decade of exploring the cancer epigenome—biological and translational implications
Baylin, S. B., & Jones, P. A. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3130 · Cited by 2,871
Epidemiology and Risk Factors of Urothelial Bladder Cancer
Burger, M., Catto, J. W. F., Dalbagni, G., Grossman, H. B., Herr, H., Karakiewicz, P., Kassouf, W., Kiemeney, L. A., La Vecchia, C., Shariat, S., et al. (2013) · European Urology · doi:10.1016/j.eururo.2012.07.033 · Cited by 2,164
Smithers, D. W. (1956) · The Lancet · doi:10.1016/s0140-6736(56)91184-9 · Cited by 1,791
Epstein, J. I., Amin, M. B., Reuter, V. R., & Mostofi, F. K. (1998) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199812000-00001 · Cited by 1,578
Parker, N., Turk, M. J., Westrick, E., Lewis, J. D., Low, P. S., & Leamon, C. P. (2005) · Analytical Biochemistry · doi:10.1016/j.ab.2004.12.026 · Cited by 1,197
Low, P. S., Henne, W. A., & Doorneweerd, D. D. (2008) · Accounts of Chemical Research · doi:10.1021/ar7000815 · Cited by 1,173
The present and future burden of urinary bladder cancer in the world
Ploeg, M., Aben, K. K. H., & Kiemeney, L. A. (2009) · World Journal of Urology · doi:10.1007/s00345-009-0383-3 · Cited by 927
Algra, A. M., & Rothwell, P. M. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70112-2 · Cited by 831
SHIINA, S., AOYAMA, H., SHIRATORI, Y., MUTOH, H., KURITA, M., OTA, S., TERANO, A., & SUGIMOTO, T. (1990) · INVESTIGATIVE RADIOLOGY · doi:10.1097/00004424-199006000-00006 · Cited by 654
Withrow & Macewen's Small Animal Clinical Oncology
Withrow, S. J., Vail, D. M., & Page, R. L. (2019) · Medical Entomology and Zoology · Cited by 637
Telomere length and risk of incident cancer and cancer mortality
Willeit, P., Willeit, J., Mayr, A., Weger, S., Oberhollenzer, F., Brandstätter, A., Kronenberg, F., & Kiechl, S. (2010) · JAMA · doi:10.1001/jama.2010.897 · Cited by 484
The role of aspirin in cancer prevention
Thun, M. J., Jacobs, E. J., & Patrono, C. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.199 · Cited by 481
Promotion of Bladder Cancer Development and Progression by Androgen Receptor Signals
Miyamoto, H., Yang, Z., Chen, Y.-T., Ishiguro, H., Uemura, H., Kubota, Y., Nagashima, Y., Chang, Y.-J., Hu, Y.-C., Tsai, M.-Y., et al. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djk113 · Cited by 401
Y. Maximov, P., M. Lee, T., & Craig Jordan, V. (2013) · Current Clinical Pharmacology · doi:10.2174/1574884711308020006 · Cited by 376
Occupational Pesticide Exposures and Cancer Risk: A Review
Alavanja, M. C. R., & Bonner, M. R. (2012) · Journal of Toxicology and Environmental Health, Part B · doi:10.1080/10937404.2012.632358 · Cited by 371
Targeted drug delivery via folate receptors
Zhao, X., Li, H., & Lee, R. J. (2008) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.5.3.309 · Cited by 358
Uroplakins in urothelial biology, function, and disease
Wu, X.-R., Kong, X.-P., Pellicer, A., Kreibich, G., & Sun, T.-T. (2009) · Kidney International · doi:10.1038/ki.2009.73 · Cited by 354
Comparative Longevity of Pet Dogs and Humans: Implications for Gerontology Research
Patronek, G. J., Waters, D. J., & Glickman, L. T. (1997) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/52a.3.b171 · Cited by 335
Piroxicam Therapy in 34 Dogs With Transitional Cell Carcinoma of the Urinary Bladder
Knapp, D. W., Richardson, R. C., Chan, T. C. K., Bottoms, G. D., Widmer, W. R., DeNicola, D. B., Teclaw, R., Bonney, P. L., & Kuczek, T. (1994) · Journal of Veterinary Internal Medicine · doi:10.1111/j.1939-1676.1994.tb03232.x · Cited by 303
Self-citationTumor Content of the Antiapoptosis Molecule Survivin and Recurrence of Bladder Cancer
Swana, H. S., Grossman, D., Anthony, J. N., Weiss, R. M., & Altieri, D. C. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410614 · Cited by 301
Epidemiology of Bladder Cancer
Silverman, D. T., Hartge, P., Morrison, A. S., & Devesa, S. S. (1992) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(18)30360-5 · Cited by 288
Mohammed, S. I., Knapp, D. W., Bostwick, D. G., Foster, R. S., Khan, K. N. M., Masferrer, J. L., Woerner, B. M., Snyder, P. W., & Koki, A. T. (1999) · PubMed · Cited by 285
Self-citationMitra, A. P., Datar, R. H., & Cote, R. J. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.2073 · Cited by 284
Canine Transitional Cell Carcinoma
Mutsaers, A. J., Widmer, W. R., & Knapp, D. W. (2003) · Journal of Veterinary Internal Medicine · doi:10.1111/j.1939-1676.2003.tb02424.x · Cited by 281
Self-citationEpidemiology of urinary bladder cancer: from tumor development to patient’s death
Murta-Nascimento, C., Schmitz-Dräger, B. J., Zeegers, M. P., Steineck, G., Kogevinas, M., Real, F. X., & Malats, N. (2007) · World Journal of Urology · doi:10.1007/s00345-007-0168-5 · Cited by 254
Higgins, J. P. T., Kaygusuz, G., Wang, L., Montgomery, K., Mason, V., Zhu, S. X., Marinelli, R. J., Presti, J. C., van de Rijn, M., & Brooks, J. D. (2007) · American Journal of Surgical Pathology · doi:10.1097/01.pas.0000213438.01278.5f · Cited by 237
Neutering dogs: effects on joint disorders and cancers in golden retrievers
Torres de la Riva, G., Hart, B. L., Farver, T. B., Oberbauer, A. M., Messam, L. L. M., Willits, N., & Hart, L. A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055937 · Cited by 235
Miyamoto, H., Yao, J. L., Chaux, A., Zheng, Y., Hsu, I., Izumi, K., Chang, C., Messing, E. M., Netto, G. J., & Yeh, S. (2012) · BJU International · doi:10.1111/j.1464-410x.2011.10706.x · Cited by 223
Man's Best Friend Becomes Biology's Best in Show: Genome Analyses in the Domestic Dog
Parker, H. G., Shearin, A. L., & Ostrander, E. A. (2010) · Annual Review of Genetics · doi:10.1146/annurev-genet-102808-115200 · Cited by 221
Chang, C., Lee, S. O., Yeh, S., & Chang, T. M. (2014) · Oncogene · doi:10.1038/onc.2013.274 · Cited by 213
Li, Y., Hwang, T. H., Oseth, L. A., Hauge, A., Vessella, R. L., Schmechel, S. C., Hirsch, B., Beckman, K. B., Silverstein, K. A., & Dehm, S. M. (2012) · Oncogene · doi:10.1038/onc.2011.637 · Cited by 202
Mohammed, S. I., Bennett, P. F., Craig, B. Α., Glickman, N. W., Mutsaers, A. J., Snyder, P. W., Widmer, W. R., DeGortari, A. E., Bonney, P. L., & Knapp, D. W. (2002) · PubMed · Cited by 197
Self-citationKoutros, S., Lynch, C. F., Ma, X., Lee, W. J., Hoppin, J. A., Christensen, C. H., Andreotti, G., Freeman, L. B., Rusiecki, J. A., Hou, L., et al. (2008) · International Journal of Cancer · doi:10.1002/ijc.24020 · Cited by 177
A population study of neutering status as a risk factor for canine prostate cancer
Bryan, J. N., Keeler, M. R., Henry, C. J., Bryan, M. E., Hahn, A. W., & Caldwell, C. W. (2007) · The Prostate · doi:10.1002/pros.20590 · Cited by 176
Preclinical Evaluation of EC145, a Folate-Vinca Alkaloid Conjugate
Reddy, J. A., Dorton, R., Westrick, E., Dawson, A., Smith, T., Xu, L.-C., Vetzel, M., Kleindl, P., Vlahov, I. R., & Leamon, C. P. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0033 · Cited by 176
Non-steroidal anti-inflammatory drugs to potentiate chemotherapy effects: From lab to clinic
de Groot, D. J. A., de Vries, E. G. E., Groen, H. J. M., & de Jong, S. (2007) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2006.07.001 · Cited by 175
Low-dose metronomic chemotherapy: A systematic literature analysis
Lien, K., Georgsdottir, S., Sivanathan, L., Chan, K., & Emmenegger, U. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.06.038 · Cited by 170
Mesothelioma in pet dogs associated with exposure of their owners to asbestos
Glickman, L. T., Domanski, L. M., Maguire, T. G., Dubielzig, R. R., & Churg, A. (1983) · Environmental Research · doi:10.1016/0013-9351(83)90114-7 · Cited by 163
Epidemiologic study of insecticide exposures, obesity, and risk of bladder cancer in household dogs
Glickman, L. T., Schofer, F. S., McKee, L. J., Reif, J. S., & Goldschmidt, M. H. (1989) · Journal of Toxicology and Environmental Health · doi:10.1080/15287398909531360 · Cited by 158
Glickman, L. T., Raghavan, M., Knapp, D. W., Bonney, P. L., & Dawson, M. H. (2004) · Journal of the American Veterinary Medical Association · doi:10.2460/javma.2004.224.1290 · Cited by 152
Self-citationVeterinary Co‐operative Oncology Group
Vail, D. M. (2004) · Veterinary and Comparative Oncology · doi:10.1111/j.1476-5810.2004.0053a.x · Cited by 150
Endogenous gonadal hormone exposure and bone sarcoma risk.
Cooley, D. M., Beranek, B. C., Schlittler, D. L., Glickman, N. W., Glickman, L. T., & Waters, D. J. (2002) · PubMed · Cited by 145
Dill, A. L., Ifa, D. R., Manicke, N. E., Costa, A. B., Ramos, J. A., Knapp, D. W., & Cooks, R. G. (2009) · Analytical Chemistry · doi:10.1021/ac901028b · Cited by 134
Self-citationNars, M. D. S., & Kaneno, R. (2012) · International Journal of Cancer · doi:10.1002/ijc.27801 · Cited by 134
Hormonal and Sex Impact on the Epidemiology of Canine Lymphoma
Villamil, J. A., Henry, C. J., Hahn, A. W., Bryan, J. N., Tyler, J. W., & Caldwell, C. W. (2009) · Journal of Cancer Epidemiology · doi:10.1155/2009/591753 · Cited by 134
Shirahama, T. (2000) · PubMed · Cited by 133
Pet dogs as sentinels for environmental contamination
Backer, L. C., Grindem, C. B., Corbett, W. T., Cullins, L. D., & Hunter, J. L. (2001) · The Science of The Total Environment · doi:10.1016/s0048-9697(01)00740-9 · Cited by 128
Phase I trial of piroxicam in 62 dogs bearing naturally occurring tumors
Knapp, D. W., Richardson, R. C., Bottoms, G. D., Teclaw, R. F., & Chan, T. (1992) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00686255 · Cited by 125
Self-citationDill, A. L., Eberlin, L. S., Costa, A. B., Zheng, C., Ifa, D. R., Liang Cheng, C., Masterson, T. A., Koch, M. O., Vitek, O., & Cooks, R. G. (2011) · Chemistry - A European Journal · doi:10.1002/chem.201001692 · Cited by 118
Pathology of canine bladder and urethral cancer and correlation with tumour progression and survival
Valli, V. E., Norris, A. M., Jacobs, R. M., et al. (1995) · Journal of Comparative Pathology · doi:10.1016/s0021-9975(05)80027-1 · Cited by 115
Prevalence of Telomerase Activity in Human Cancer
Chen, C., & Chen, R. (2011) · Journal of the Formosan Medical Association · doi:10.1016/s0929-6646(11)60043-0 · Cited by 102
The origins of urothelial carcinoma
Liang Cheng, C., Davidson, D. D., MacLennan, G. T., Williamson, S. R., Zhang, S., Koch, M. O., Montironi, R., & Antonio Lopez-beltran, B. (2010) · Expert Review of Anticancer Therapy · doi:10.1586/era.10.73 · Cited by 98
Epidemiologic Studies of Risk Factors for Cancer in Pet Dogs
Kelsey, J. L., Moore, A. S., & Glickman, T. (1998) · Epidemiologic Reviews · doi:10.1093/oxfordjournals.epirev.a017981 · Cited by 93
Hsu, I., Chuang, K., Slavin, S. A., Da, J., Lim, W.-X., Pang, S.-T., O’Brien, J. H., & Yeh, S. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt348 · Cited by 92
Schrempp, D., Childress, M. O., Stewart, J. C., Leach, T. N., Tan, K. M., Abbo, A. H., de Gortari, A. E., Bonney, P. L., & Knapp, D. W. (2013) · Journal of the American Veterinary Medical Association · doi:10.2460/javma.242.11.1534 · Cited by 88
Self-citationRXRα: Novel Target for Prostate Cancer
Pandey, K. K., & Batra, S. K. (2003) · Cancer Biology & Therapy · doi:10.4161/cbt.2.2.350 · Cited by 84
Shariat, S. F., Karakiewicz, P. I., Godoy, G., Karam, J. A., Ashfaq, R., Fradet, Y., Isbarn, H., Montorsi, F., Jeldres, C., Bastian, P. J., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2554 · Cited by 78
Chemotherapy in advanced bladder cancer: current status and future
Ismaili, N., Amzerin, M., & Fléchon, A. (2011) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-4-35 · Cited by 77
The Role of the Androgen Receptor in the Development and Progression of Bladder Cancer
Li, Y., Izumi, K., & Miyamoto, H. (2012) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hys072 · Cited by 77
Prognostic Value of Cell-Cycle Regulation Biomarkers in Bladder Cancer
Mitra, A. P., Hansel, D. E., & Côté, R. J. (2012) · Seminars in Oncology · doi:10.1053/j.seminoncol.2012.08.008 · Cited by 76
TELOMERASE IN UROLOGICAL MALIGNANCY
Orlando, C., Gelmini, S., Selli, C., & Pazzagli, M. (2001) · The Journal of Urology · doi:10.1016/s0022-5347(05)66040-5 · Cited by 68
Targeting Folate Receptors to Treat Invasive Urinary Bladder Cancer
Dhawan, D., Ramos‐Vara, J. A., Naughton, J. F., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2101 · Cited by 65
Self-citationAlterations of DNA methylome in human bladder cancer
Nia, A. B., Cockburn, M., & Tommasi, S. (2013) · Epigenetics · doi:10.4161/epi.25927 · Cited by 62
Identification of a bladder cancer-specific ligand using a combinatorial chemistry approach
Zhang, H., Aina, O. H., Lam, K. S., White, R. D., Evans, C. P., Henderson, P. T., Lara, P. N., Wang, X., Bassuk, J. A., & Pan, C.-X. (2010) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2010.06.011 · Cited by 55
Cyclooxygenase inhibitors in urinary bladder cancer: in vitro and in vivo effects
Mohammed, S. I., Dhawan, D., Abraham, S., Snyder, P. W., Waters, D. J., Craig, B. Α., Lu, M., Wu, L., Zheng, R., Stewart, J. C., et al. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0117 · Cited by 55
Self-citationGene polymorphisms in bladder cancer
Franekova, M., Halášová, E., Bukovska, E., Ľupták, J., & Dobrota, D. (2007) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2006.10.011 · Cited by 54
Dhawan, D., Craig, B. Α., Liang Cheng, C., Snyder, P. W., Mohammed, S. I., Stewart, J. C., Zheng, R., Loman, R. A., Foster, R. S., & Knapp, D. W. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0049 · Cited by 54
Self-citationMolecular Imaging of Cyclooxygenase-2 in Canine Transitional Cell Carcinomas In Vitro and In Vivo
Cekanova, M., Uddin, M. J., Bartges, J. W., Callens, A. J., Legendre, A. Μ., Rathore, K., Wright, L., Carter, A. G., & Marnett, L. J. (2013) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-12-0358 · Cited by 51
Urine survivin as a diagnostic biomarker for bladder cancer: a systematic review
Ku, J. H., Godoy, G., Amiel, G. E., & Lerner, S. P. (2012) · British Journal of Urology · doi:10.1111/j.1464-410x.2011.10884.x · Cited by 47
Raghavan, M., Knapp, D. W., Bonney, P. L., Dawson, M. H., & Glickman, L. T. (2005) · Journal of the American Veterinary Medical Association · doi:10.2460/javma.2005.227.94 · Cited by 46
Self-citationRaghavan, M., Knapp, D. W., Dawson, M. H., Bonney, P. L., & Glickman, L. T. (2004) · Journal of the American Veterinary Medical Association · doi:10.2460/javma.2004.225.389 · Cited by 42
Self-citationDNMT1: An emerging target in the treatment of invasive urinary bladder cancer
Dhawan, D., Ramos‐Vara, J. A., Hahn, N. M., Waddell, J. N., Olbricht, G. R., Zheng, R., Stewart, J. C., & Knapp, D. W. (2012) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2012.03.015 · Cited by 42
Self-citationEmerging therapies in metastatic castration-sensitive and castration-resistant prostate cancer
MacVicar, G. R., & Hussain, M. (2013) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32835ff161 · Cited by 40
Dhawan, D., Jeffreys, A. B., Zheng, R., Stewart, J. C., & Knapp, D. W. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0313 · Cited by 38
Self-citationEstrogen receptor-β expression and pharmacological targeting in bladder cancer
KAUFFMAN, E. C., Robinson, B. D., Downes, M., Marcinkiewicz, K. M., Vourganti, S., Scherr, D. S., Gudas, L. J., & Mongan, N. P. (2013) · Oncology Reports · doi:10.3892/or.2013.2416 · Cited by 36
Cancer Incidence in Korean Vietnam Veterans During 1992-2003: The Korean Veterans Health Study
Yi, S. (2013) · Journal of Preventive Medicine and Public Health · doi:10.3961/jpmph.2013.46.6.309 · Cited by 28
Current treatment of metastatic bladder cancer and future directions
Lei, A. Q., Liang Cheng, C., & Pan, C.-X. (2011) · Expert Review of Anticancer Therapy · doi:10.1586/era.11.181 · Cited by 28
Implication of androgen receptor in urinary bladder cancer: a critical mini review.
Rahmani, A. H., Alzohairy, M. A., Babiker, A. Y., Khan, A. A., Aly, S. M., & Rizvi, M. M. A. (2013) · Europe PMC (PubMed Central) · Cited by 25
Cited by
Comparative oncology: what dogs and other species can teach us about humans with cancer
Schiffman, J. D., & Breen, M. (2015) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2014.0231 · Cited by 418
Gardner, H. L., Fenger, J. M., & London, C. A. (2016) · Annual Review of Animal Biosciences · doi:10.1146/annurev-animal-022114-110911 · Cited by 215
Metadata
- Authors
- Knapp, D. W., Ramos-Vara, J. A., Moore, G. E., Dhawan, D., Bonney, P. L., & Young, K. E.
- Venue
- ILAR Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-01-01
- Volume
- 55
- Issue
- 1
- Pages
- 100-118
- ISSN
- 1084-2020 (ISSN-L)
- OpenAlex
- W2169963604
- Cited by
- 284
- References
- 80
- FWCI
- 10.66
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.